deucravacitinib,apremilast
bms,amgen
['apremilast', 'psoriasis', 'deucrava', 'deucra', 'otezla', '$amgn', '$bmy']
$bmy wins fda approval for tyk2 inhibitor sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis, hoping to unseat $amgn otezla (apremilast) as the standard-of-care oral therapy in the disease. (scrip $) 
I am Managing Editor, US Commercial News, for the Informa Pharma Insights publications Scrip and The Pink Sheet. Views expressed here are strictly my own.